111. “Passive Nanoparticles for Organ-Selective Systemic Delivery: Design, Mechanism and Perspective”

110. “Intertumoral Delivery of OVA-mRNA loaded on Positive Charge Hyper Branched Cyclodextrin Based Polymer Induced an Anti-tumour Immunological Response Against Melanoma”

109. “A large scale machine learning analysis of inorganic nanoparticles in preclinical cancer research”

108. “Bioengineered metastatic cancer nanovaccine with a TLR7/8 agonist for needle-free intranasal immunization”

107. “Bioinspired and biomimetic cancer cell-membrane derived nanovesicles for tumor-targeted nanotheranostics ”

106. “A Fluorinated BODIPY-Based Zirconium Metal-Organic Framework for in vivo Enhanced Photodynamic Therapy”

105. “Cathepsin B processing is required for the in vivo efficacy of Albumin-Drug Conjugates”

104. “The state of health in the European Union (EU-27) in 2019: A systematic analysis for the Global Burden of Disease Study 2019”

103. “The global burden of acute versus chronic care needs: Analysis of the Global Burden of Disease Study 2019”

102. “Evolution of CRISPR-enabled biosensors for amplification-free nucleic acid detection”

101. “A Receptor-mediated Landscape of Druggable and Targeted Nanomaterials for Gliomas”

100. “Highlight: Biomimetic hydrogel supporting baths as an alternative to initiate and maintain breast tumor-derived organoids culture”

99. “Bioengineered exosome membrane camouflaged-abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine”

98. “mRNA therapy at the convergence of genetics and nanomedicine”

97. “Hydrogels for RNA delivery”
 

96. “Biopolymeric coatings for local release of therapeutics from biomedical implants”

95. “Exosome Membrane-Coated Nanosystems: Exploring Biomedical Applications in Cancer Diagnosis and Therapy”

94. “Technological challenges of biomembrane-coated top-down cancer nanotherapy”

93. “Using gold-nanobeacons as a theranostic technique to recognize, detect and inhibit specific nucleic acids”

92. “Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer”

91. “The global burden of cancer attributable to risk factors, 2010–2019: a systematic analysis for the Global Burden of Disease Study 2019”

90. “Nucleic acid-based therapy for brain cancer: Challenges and strategies”

89. “Gold nanoconjugates for miRNA modulation in cancer therapy: from miRNA silencing to miRNA mimics”

88. “Macrophage cell membrane-cloaked nanoplatforms in biomedical applications”

87. “Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019”

86. “PrimeView - Nanodelivery of nucleic acids”
 

86. “Nanodelivery of nucleic acids”
 

85. “Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019”

84. “Bioinspired Soft Nanovesicles as Site-Selective Imaging and Targeted Therapies for Cancer”
 

83. “The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019”
 

82. “Prodrug polymeric nanoconjugates encapsulating gold nanoparticles for enhanced X-Ray radiation therapy in breast cancer”
 

81. “Controlled delivery of gold nanoparticle-coupled miRNA therapeutics via an injectable self-healing hydrogel”
 

80. “Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019”

79. “Machine learning for next generation nanotechnology in healthcare”

 

78. “Facts and Figures on Materials Science and Nanotechnology Progress and Investment”
 

77. “Global, regional, and national progress toward Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019”

76. “Nanomedicine-based strategies to target and modulate the tumor microenvironment”
 

75. “Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression”
 

74. “CRISPR Systems for COVID-19 Diagnosis”

 

73. “Ultrahigh penetration and retention of graphene quantum dot mesoporous silica nanohybrids for image guided tumor regression”
 

72. “Osteogenic Differentiation of Human Mesenchymal Stem Cells by the Single Action of Luminescent Polyurea Oxide Biodendrimers”
 

71. “Revisiting Gene Delivery to the Brain: Silencing and Editing”
(2021 Biomaterials Science Emerging Investigators Issue)
 

70. “Swallowing the doctor”: an interview with João Conde about the future of nanomedicine”
 

69. “Biomimetic cancer cell membrane coated-nanosystems as next-generation cancer therapies”
 

68. “Why Go NANO on COVID-19 pandemic?”

 

67. “Nanotechnology-based disinfectants and sensors for SARS-CoV-2”

 

66. “Tetrazine carbon nanotubes for pretargeted in vivo ‘click-to-release’ bioorthogonal imaging” (VIP paper)
 

65. “Localized Nanotheranostics: Recent developments in Cancer Nanomedicine”
 

64. “Platinum-triggered Bond-cleavage of Pentynoyl amide and N-propargyl handles for Drug-Activation”
 

63. “Stepwise Assembly of Multimode Liposomal Nanotheranostic Agent for Targeted In Vivo Bioimaging and NIR Light Mediated Cancer Therapy”
 

62. “Above and beyond Cancer Therapy: translating biomaterials into clinics”
 

61. “Prolonged local in vivo delivery of stimuli-responsive nanogels that rapidly release doxorubicin in triple-negative breast cancer cells”
 

60. “Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression”

59. “Cisplatin-Triggered Bioorthogonal Decaging of Amide Bonds for Targeted-Drug Activation in vivo”
 

58. “Oral pH sensitive GNS@ab Nanoprobes for targeted therapy of Helicobacter Pylori without disturbance gut microbiome”
 

57. “Gastric parietal cell and Intestinal goblet cell secretion: a novel cell-mediated in vivo nanoparticle clearance pathway enhanced with diarrhea via Chinese Herbs”

56. “Biopolymers for anti-tumor implantable drug delivery systems: Recent advances and future outlook”
 

55. “Ferritin nanocarrier traverses the blood brain barrier and kills glioma”
 

54. “Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells”
 

53. “Plasmonic gold nanoparticles for detection of fungi and human cutaneous fungal infections”
 

52. “Smart NIR linear and nonlinear optical nanomaterials for cancer theranostics: prospects in photomedicine”
 

51. “Fullerene: Biomedical Engineers Get to Revisit an Old Friend”

 

50. “Designing Hydrogels for On-Demand Therapy”

 

49. “Local microRNA delivery targets Palladin and prevents metastatic breast cancer”
 

48. “Chiral Antioxidant-based Gold Nanoclusters Reprogram DNA Epigenetic Patterns”
 

47. “Gold Nanostars for efficient in Vitro and in Vivo Real-Time SERS Detection and Drug Delivery via Plasmonic-Tunable Raman/FTIR Imaging”
 

46. “Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model”

45. “Revisiting the classification of NIR-absorbing/emitting nanomaterials for in vivo bioapplications”
 

44. “Biomaterials for Metastasis: Bridging the Gap between Basic and Translational Research”
 

43. “Revisiting the ‘one material fits all’ rule for cancer nanotherapy”

 

42. “3D Hydrogel Scaffold Doped With 2D Graphene Materials For Biosensors And Bioelectronics”
 

41. “Gold Nanoprisms as a hybrid in vivo Cancer Theranostic platform for in situ Photoacoustic Imaging, Angiography and localized Hyperthermia”
 

40. “Dual-Color Emissive Upconversion Nanocapsules for Differential Cancer Bioimaging in vivo”
 

39. “Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment”
 

38. “EDITORIAL: Cancer Nanotheranostics - What have we learned so far?”

 

37. “The Golden Age in Cancer Nanobiotechnology: Quo vadis?”

 

36. “RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?”

​

35. “Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis”
 

34. “15 years on siRNA delivery: beyond the State-of-the-Art on inorganic nanoparticles for RNAi Therapeutics”
 

33. “Significance of the balance between intracellular glutathione and polyethylene glycol for successful release of small interfering RNA from gold nanoparticles”

32. “Gold Nanoparticle-siRNA Mediated Oncogene Knockdown at RNA and Protein level, with associated Gene effects”
 

31. “Investigating the role of shape on the biological impact of gold nanoparticles in vitro”
 

30. “Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells”

29. “POxylated polyurea dendrimers: Smart core-shell vectors with IC50 lowering capacity”
 

28. “RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing”
 

27. “The next generation of smart gold nanobeacons: nanotheranostics is ready for prime-time”
 

26. “Personalizing biomaterials for precision nanomedicine in light of local tissue microenvironment”
 

25. “Implantable hydrogel embedded dark-gold nanoswitch as a theranostics probe to sense and overcome cancer multidrug resistance”

​

24. “Are RNAi and miRNA therapeutics truly dead?”

 

23. “Target-Responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-all-trades in cancer nanotheranostics?”
 

22. “Polyurea dendrimer for efficient cytosolic siRNA delivery”

 

21. “A promising road with challenges: where gold nanoparticles are in translational research?”
 

20. “Revisiting 30 years of Biofunctionalization and Surface Chemistry of Inorganic Nanoparticles for Nanomedicine”
 

19. “Antibody-Drug Gold Nanoantennas with Raman spectroscopic fingerprints for in vivo tumour Theranostics”
 

18. “A Gold-nanobeacon system for Gene therapy: evaluation of Genotoxicity, Cell toxicity and Proteome profiling analysis”
 

17. “Gold-Nanobeacons as a theranostic system for the detection and inhibition of specific genes”
 

16. “Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?”
 

15. “In vivo tumour targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models”
 

14. “Gold-Nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events”
 

13. “Design of Multifunctional Gold Nanoparticles for in vitro and in vivo Gene Silencing”
 

12. “Effect of PEG biofunctional spacers and TAT peptide on dsRNA loading on Gold Nanoparticles”
 

11. “Modification of Plasmid DNA Topology by Histone-Mimetic Gold Nanoparticles”
 

10. “Gold-Nanobeacons for Real-Time Monitoring of RNA Synthesis”

 

9. “Genotoxic effects of occupational exposure to lead and influence of polymorphisms in genes involved in lead toxicokinetics and in DNA repair”

8. “Noble Metal Nanoparticles for Biosensing Applications”

 

7. “Noble Metal Nanoparticles Applications in Cancer”

 

6. “Nanophotonics for Molecular Diagnostics and Therapy Applications”

 

5. “Alloy Metal Nanoparticles for Multicolour Cancer Diagnostics”

 

4. “In vitro Transcription and Translation Inhibition via DNA functionalized Gold Nanoparticles”
 

3. “Use of Cyclodextrins as Scavengers of Inhibitory Photo-products in Light controlled in vitro Synthesis of RNA”
 

2. “RNA Quantification using Gold Nanoprobes - application to Cancer Diagnostics”
 

1. “Association of common variants in Mismatch Repair Genes and Breast Cancer susceptibility: a Multigene study”